CD274 and pancreatic adenocarcinoma: The identification of CD274 mutations as a risk factor in at least one survival metric in patients with GBM, LGG, and PAAD (Supplementary Figure S9) aligns with previously reported associations (Zeng et al., 2023; Chen et al., 2018; Fen et al., 2017).